Chimeric Therapeutics Ltd has released a press release.
Chimeric opens CHM CDH17 Phase 1/2 trial
Filed with ASX ·
6ix hasn’t read this filing yet.
Chimeric Therapeutics Limited on 6ix
Earlier from Chimeric Therapeutics
- CHM CDH17 Phase 1/2 clinical trial approved for initiation
- Resignation of CEO and Managing Director
- Clinical milestones for 2024 & 2023 successes highlighted
- Half Yearly Report and Accounts
- 1st patient treated in ADVENT-AML Phase 1b clinical trial
Later from Chimeric Therapeutics
- Phase 1b ADVENT-AML trial of CHM CORE-NK advances at MDA
- First patient enrolled in CHM CDH17 Phase 1/2 clinical trial
- First patient dosed in Phase 1/2 trial of CHM CDH17
- Appendix 4E and Preliminary Final Report
- AML patient achieves Complete Response in CHM CORE-NK trial
Follow Chimeric Therapeutics into a list and get an email when it puts out news.
Follow Chimeric Therapeutics